Q5S007 (LRRK2_HUMAN) Homo sapiens (Human)
Leucine-rich repeat serine/threonine-protein kinase 2 UniProtKBInterProSTRINGInteractive Modelling
2527 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
44 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Cryo-EM structure of Rab12-LRRK2 complex in the LRRK2 monomer state |
Heteromer Q6IQ22; | 99.91 | 1×GDP; 1×ANP; 1×MG; 1×GNP; | |||
| Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 monomer state |
Heteromer O14966; | 99.91 | 1×MG; 1×GNP; 1×GDP; 1×ATP; | |||
| Cryo-EM structure of Rab12-LRRK2 complex in the LRRK2 dimer state |
Heteromer Q6IQ22; | 99.91 | 2×GDP; 2×ANP; 2×MG; 2×GNP; | |||
| Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 dimer state |
Heteromer O14966; | 99.91 | 2×GDP; 2×ATP; | |||
| Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 tetramer state |
Heteromer O14966; | 99.83 | 4×GDP; 4×ATP; | |||
| Structure of full length LRRK2 bound to GZD-824 (I2020T mutant) |
Heteromer | 99.94 | 1×GDP; 1×T3X; | |||
| Structure of full-length LRRK2 bound to MLi-2 (I2020T mutant) |
Heteromer | 100.0 | 1×A1N; 1×GDP; | |||
| Structure of the LRRK2/14-3-3 complex |
Heteromer P61981; | 100.0 | 1×GDP; | |||
| Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Rep… |
Heteromer | 100.0 | ||||
| Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Rep… |
Heteromer | 100.0 | 1×GDP; 1×MG; | |||
| Structure of the C-terminal half of LRRK2 bound to RN277 (Type-II inhibitor) |
Heteromer | 100.0 | 1×A1A7Q; | |||
| Structure of the C-terminal half of LRRK2 bound to GZD-824 (G2019S mutant) |
Heteromer | 99.9 | 1×T3X; | |||
| Structure of C-terminal LRRK2 bound to MLi-2 (G2019S mutant) |
Heteromer | 99.89 | 1×A1N; 1×GDP; | |||
| Structure of the C-terminal half of LRRK2 bound to GZD-824 (I2020T mutant) |
Heteromer | 100.0 | 1×T3X; | |||
| C-terminal LRRK2 bound to E11 DARPin |
Heteromer | 100.0 | ||||
| Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS910 |
Heteromer P31947; | 100 | 4×CA; 2×CL; 2×NA; | |||
| Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS935 |
Heteromer P31947; | 100 | 6×CA; 2×CL; | |||
| Structure of the LRRK2 dimer | homo-2-mer | 99.89 | 2×GDP; 2×ATP; | |||
| Cryo-EM structure of LRRK2 bound to type II inhibitor rebastinib | homo-2-mer | 99.94 | 2×GDP; 2×919; | |||
| Cryo-EM structure of LRRK2 bound to type II inhibitor GZD824 | homo-2-mer | 99.94 | 2×GDP; 2×T3X; | |||
| Cryo-EM structure of LRRK2 bound to type II inhibitor ponatinib | homo-2-mer | 99.94 | 2×0LI; 2×GDP; | |||
| Integrative in situ structure of Parkinsons disease-linked human LRRK2 | homo-2-mer | 99.9 | ||||
| Crystal structure of LRRK2 WD40 domain dimer | homo-2-mer | 100.0 | ||||
| Crystal structure of LRRK2 WD40 domain dimer | homo-2-mer | 100.0 | 6×PT; | |||
| Dimeric structure of LRRK2 GTPase domain | homo-2-mer | 98.94 | 4×MG; 2×GDP; | |||
| Dimeric structure of LRRK2 GTPase domain | homo-2-mer | 100 | 4×MG; 2×GDP; | |||
| LRRK2 Roc domain RP (Ras-pocket) complexed to Divarasib | homo-2-mer | 95.15 | 2×GDP; 3×BR; 2×MG; 1×F; 2×A1AWR; 1×IOD; | |||
| 1.9A crystal structure of the GTPase domain of Parkinson's disease-associated protein LRRK2 carryin… | homo-2-mer | 98.26 | 2×MG; 2×GDP; | |||
| Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 re… | homo-2-mer | 100.0 | 2×MG; 2×GDP; | |||
| Structure of the LRRK2 monomer | monomer | 99.89 | 1×GDP; 1×ATP; | |||
| Autoinhibited full-length LRRK2(I2020T) on microtubules with MLi-2 | monomer | 100.0 | 1×GDP; 1×A1N; | |||
| Structure of LRRK2 after symmetry expansion | monomer | 99.89 | 1×GDP; 1×ATP; | |||
| Structure of the LRRK2 G2019S mutant | monomer | 99.83 | 1×GDP; 1×ATP; | |||
| Cryo-EM structure of LRRK2 bound to type I inhibitor GNE-7915 | monomer | 99.73 | 1×GDP; 1×A0T; | |||
| Cryo-EM structure of LRRK2 bound to type I inhibitor LRRK2-IN-1 | monomer | 99.74 | 1×GDP; 1×4K4; | |||
| Cryo-EM structure of LRRK2 bound with type-I inhibitor DNL201 | monomer | 99.72 | 1×GDP; 1×TVT; | |||
| Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Rep… | monomer | 100.0 | 1×GDP; 1×MG; | |||
| Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Rep… | monomer | 100.0 | ||||
| Structure of C-terminal LRRK2 bound to MLi-2 (I2020T mutant) | monomer | 99.89 | 1×A1N; 1×GDP; 1×MG; | |||
| Structure of C-terminal LRRK2 bound to MLi-2 | monomer | 100.0 | 1×A1N; 1×GDP; | |||
| Structure of C-terminal half of LRRK2 bound to GZD-824 | monomer | 100.0 | 1×T3X; | |||
| Structure of Leucine Rich Repeat Kinase 2's ROC domain interacting with the microtubule facing the … | monomer | 100 | 1×GDP; | |||
| Structure of Leucine Rich Repeat Kinase 2's ROC domain interacting with the microtubule facing the … | monomer | 100 | 1×GDP; | |||
| Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 re… | monomer | 100.0 | 1×MG; 1×GDP; | |||
6 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8fo9.1.B | monomer | 0.74 | 1×GDP; 1×ATP; | 99.88 | ||
| 9ci3.1.C | monomer | 0.70 | 1×GDP; | 99.96 | ||
| 8u8b.1.A | monomer | 0.68 | 99.88 | |||
| 8tzf.1.A | monomer | 0.67 | 1×T3X; | 99.96 | ||
| 8tzh.1.B | monomer | 0.64 | 1×A1N; | 100.00 | ||
| 6ojf.1.B | monomer | 0.62 | 1×MG; 1×GDP; | 92.15 | ||